-
In a Phase 2 trial, Ludwig and colleagues present data on 79 patients with relapsed or refractory myeloma who were treated with bendamustine in combination with bortezomib and dexamethasone.
-
In a Phase 3, randomized clinical trial of primary systemic therapy for patients with early, locally advanced breast cancer, the addition of capecitabine to each of six 3-weekly cycles of epirubicin-docetaxel resulted in a 1.64 fold increase in the possibility of primary tumor pathologic complete response.
-
The association between oral contraceptive use and ovarian or breast cancer in BRCA1 or BRCA2 mutation carriers are qualitatively similar to associations reported in the general population.
-
This paper represents the largest collection of cases with central path review and provides better clarity to prognostic factors previously intimated from retrospective work.
-
It is indeed ironic that 16 years after the landmark Burris study, innovations in pancreatic cancer treatment still lack essential quality-of-life data.
-
Calculating 60-day mortality risk by these readily available parameters (ECOG PS and WBC) can be used to identify high-risk patients who may require heightened surveillance after standard or experimental chemotherapy or, alternatively, a reduction in treatment intensity.
-
Hopefully, as multi-institution, randomized trials are developed for second-line treatment of pancreatic cancer, CA19-9 levels will be included both pre- and post-first cycle treatment and responses compared with the established RECIST criteria.
-
In this large, retrospective cohort study, women with a history of bariatric surgery were at a small increased risk of both spontaneous and medically indicated preterm birth and small for gestational age births.
-
Long-term complications, particularly secondary cancers, were significantly more common in patients receiving whole pelvic radiation (vs brachytherapy alone) for early-stage endometrial cancer.
-
Women presenting for emergency contraception were offered a copper IUD or Plan B. Those who chose an IUD had a lower cumulative risk of unintended pregnancy at 1 year.
